Does the media favor AUTL or MAZE?

In the previous week, Autolus Therapeutics had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Autolus Therapeutics and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Autolus Therapeutics' score of 0.85 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUTL or CMPS?

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 8 articles in the media. Compass Pathways' average media sentiment score of 1.27 beat Autolus Therapeutics' score of 0.85 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUTL or NTLA?

In the previous week, Autolus Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Autolus Therapeutics and 5 mentions for Intellia Therapeutics. Autolus Therapeutics' average media sentiment score of 0.85 beat Intellia Therapeutics' score of 0.48 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SEPN or AUTL?

In the previous week, Autolus Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Autolus Therapeutics' score of 0.85 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVBP or AUTL?

In the previous week, Autolus Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 8 mentions for Autolus Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.26 beat Autolus Therapeutics' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Autolus Therapeutics (AUTL) Competitors

$1.82 +0.33 (+22.15%)

Closing price 04:00 PM Eastern

Extended Trading

$1.82 +0.00 (+0.05%)

As of 05:09 PM Eastern

Compare

AUTL vs. MAZE, CMPS, NTLA, SEPN, and AVBP

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Maze Therapeutics (MAZE), Compass Pathways (CMPS), Intellia Therapeutics (NTLA), Septerna (SEPN), and ArriVent BioPharma (AVBP).

How does Autolus Therapeutics compare to Maze Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Autolus Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 380.77%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 141.49%. Given Autolus Therapeutics' higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Maze Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Maze Therapeutics' return on equity of -36.62% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Autolus Therapeutics had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Autolus Therapeutics and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Autolus Therapeutics' score of 0.85 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
Maze Therapeutics	$20M	75.63	-$131.12M	-$2.53	N/A

Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Summary

Maze Therapeutics beats Autolus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Compass Pathways?

Autolus Therapeutics (NASDAQ:AUTL) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Autolus Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Autolus Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market.

Compass Pathways has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Compass Pathways' return on equity of -31.07% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Compass Pathways	N/A	-31.07%	-11.40%

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 8 articles in the media. Compass Pathways' average media sentiment score of 1.27 beat Autolus Therapeutics' score of 0.85 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 380.77%. Compass Pathways has a consensus target price of $23.36, suggesting a potential upside of 107.62%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Autolus Therapeutics beats Compass Pathways on 9 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Intellia Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Autolus Therapeutics has a net margin of -311.98% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Autolus Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 8 mentions for Autolus Therapeutics and 5 mentions for Intellia Therapeutics. Autolus Therapeutics' average media sentiment score of 0.85 beat Intellia Therapeutics' score of 0.48 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autolus Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A
Intellia Therapeutics	$67.67M	22.24	-$412.69M	-$3.54	N/A

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 380.77%. Intellia Therapeutics has a consensus price target of $20.19, indicating a potential upside of 87.44%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30

Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Summary

Autolus Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Septerna has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Septerna presently has a consensus price target of $45.89, suggesting a potential upside of 31.19%. Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 380.77%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Septerna has a net margin of -49.88% compared to Autolus Therapeutics' net margin of -311.98%. Septerna's return on equity of -12.72% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

72.8% of Autolus Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Autolus Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Autolus Therapeutics and 3 mentions for Septerna. Septerna's average media sentiment score of 1.21 beat Autolus Therapeutics' score of 0.85 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has higher earnings, but lower revenue than Autolus Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$72.26M	21.82	-$48.88M	-$0.81	N/A
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A

Summary

Septerna beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

ArriVent BioPharma has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. ArriVent BioPharma's return on equity of -48.98% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

In the previous week, Autolus Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 8 mentions for Autolus Therapeutics and 5 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.26 beat Autolus Therapeutics' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has higher earnings, but lower revenue than Autolus Therapeutics. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Autolus Therapeutics	$92.62M	5.23	-$287.53M	-$1.09	N/A

ArriVent BioPharma currently has a consensus price target of $44.83, indicating a potential upside of 51.26%. Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 380.77%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

ArriVent BioPharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Autolus Therapeutics beats ArriVent BioPharma on 10 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$484.40M	$3.51B	$6.81B	$12.69B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-1.67	7.34	281.03	25.13
Price / Sales	5.23	1,215.58	574.87	80.86
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.72	16.89	11.03	6.21
Net Income	-$287.53M	-$12.54M	$3.48B	$347.60M
7 Day Performance	24.66%	-0.63%	0.54%	0.88%
1 Month Performance	15.19%	-7.39%	-4.19%	-3.62%
1 Year Performance	-22.55%	49.17%	63.11%	20.46%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	2.5048 of 5 stars	$1.82 +22.1%	$8.75 +380.8%	-36.6%	$484.40M	$92.62M	N/A	330	News Coverage Analyst Downgrade Gap Up High Trading Volume
MAZE Maze Therapeutics	2.3073 of 5 stars	$28.69 +3.6%	$66.00 +130.0%	+80.7%	$1.53B	$167.50M	N/A	121	Positive News Insider Trade
CMPS Compass Pathways	3.3315 of 5 stars	$11.27 +0.1%	$23.36 +107.3%	+161.5%	$1.52B	N/A	N/A	120
NTLA Intellia Therapeutics	3.3093 of 5 stars	$10.67 -0.6%	$20.19 +89.2%	-7.0%	$1.50B	$67.67M	N/A	600	Positive News Upcoming Earnings
SEPN Septerna	2.6804 of 5 stars	$33.49 +1.2%	$45.89 +37.0%	+182.1%	$1.49B	$45.95M	N/A	N/A	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. MAZE, CMPS, NTLA, SEPN, and AVBP

How does Autolus Therapeutics compare to Maze Therapeutics?

Summary

How does Autolus Therapeutics compare to Compass Pathways?

Summary

How does Autolus Therapeutics compare to Intellia Therapeutics?

Summary

How does Autolus Therapeutics compare to Septerna?

Summary

How does Autolus Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. MAZE, CMPS, NTLA, SEPN, and AVBP

How does Autolus Therapeutics compare to Maze Therapeutics?

Do analysts rate AUTL or MAZE?

Do institutionals and insiders hold more shares of AUTL or MAZE?

Is AUTL or MAZE more profitable?

Does the media favor AUTL or MAZE?

Which has stronger earnings & valuation, AUTL or MAZE?

Which has more volatility and risk, AUTL or MAZE?

Summary

How does Autolus Therapeutics compare to Compass Pathways?

Which has higher valuation & earnings, AUTL or CMPS?

Which has more volatility & risk, AUTL or CMPS?

Is AUTL or CMPS more profitable?

Does the media favor AUTL or CMPS?

Do analysts prefer AUTL or CMPS?

Do insiders and institutionals have more ownership in AUTL or CMPS?

Summary

How does Autolus Therapeutics compare to Intellia Therapeutics?

Is AUTL or NTLA more profitable?

Do institutionals & insiders believe in AUTL or NTLA?

Does the media refer more to AUTL or NTLA?

Which has stronger earnings and valuation, AUTL or NTLA?

Do analysts rate AUTL or NTLA?

Which has more volatility and risk, AUTL or NTLA?

Summary

How does Autolus Therapeutics compare to Septerna?

Which has more risk and volatility, SEPN or AUTL?

Do analysts rate SEPN or AUTL?

Is SEPN or AUTL more profitable?

Do insiders and institutionals have more ownership in SEPN or AUTL?

Does the media prefer SEPN or AUTL?

Which has stronger earnings and valuation, SEPN or AUTL?

Summary

How does Autolus Therapeutics compare to ArriVent BioPharma?

Is AVBP or AUTL more profitable?

Does the media prefer AVBP or AUTL?

Which has preferable valuation and earnings, AVBP or AUTL?

Do analysts prefer AVBP or AUTL?

Which has more risk & volatility, AVBP or AUTL?

Do institutionals and insiders have more ownership in AVBP or AUTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools